Moreover, to assess whether the signature retains its predictive ability in various subgroups, we stratified subgroups by age (age ≤ 60 and age > 60), gender (female and male), tumor location (left-side and right side), TNM stage (stage I-II and stage III-IV), and KRAS mutation (yes and no). This evidence concerns the gene KRAS and neoplasm.